Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Net Cash Flow: 2022-2025

Historic Net Cash Flow for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to -$17.3 million.

  • Gossamer Bio's Net Cash Flow rose 70.46% to -$17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.5 million, marking a year-over-year increase of 64.05%. This contributed to the annual value of $14.1 million for FY2024, which is 117.59% up from last year.
  • Latest data reveals that Gossamer Bio reported Net Cash Flow of -$17.3 million as of Q3 2025, which was down 508.27% from -$2.8 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Net Cash Flow high stood at $59.6 million for Q3 2022, and its period low was -$58.5 million during Q3 2024.
  • Moreover, its 3-year median value for Net Cash Flow was -$17.2 million (2025), whereas its average is -$9.4 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 270.18% in 2024, then plummeted by 351.73% in 2025.
  • Over the past 4 years, Gossamer Bio's Net Cash Flow (Quarterly) stood at -$42.1 million in 2022, then fell by 20.30% to -$50.7 million in 2023, then spiked by 134.99% to $17.7 million in 2024, then soared by 70.46% to -$17.3 million in 2025.
  • Its Net Cash Flow stands at -$17.3 million for Q3 2025, versus -$2.8 million for Q2 2025 and -$17.2 million for Q1 2025.